[go: up one dir, main page]

WO2010066891A3 - Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients - Google Patents

Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients Download PDF

Info

Publication number
WO2010066891A3
WO2010066891A3 PCT/EP2009/066973 EP2009066973W WO2010066891A3 WO 2010066891 A3 WO2010066891 A3 WO 2010066891A3 EP 2009066973 W EP2009066973 W EP 2009066973W WO 2010066891 A3 WO2010066891 A3 WO 2010066891A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcr
treatment
fusion protein
tyrosine kinase
abl fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/066973
Other languages
French (fr)
Other versions
WO2010066891A2 (en
Inventor
Hugues De Lavallade
Daniel Birnbaum
Marie-Joëlle MOZZICONACCI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO2010066891A2 publication Critical patent/WO2010066891A2/en
Publication of WO2010066891A3 publication Critical patent/WO2010066891A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method for determining if an individual suffering from chronic myeloid leukemia (CML) is at risk of developing resistance to treatment by a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein or if the individual is likely to respond to treatment by a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein, comprising: a) determining the expression level of at least one of the genes selected from the group consisting of : RAD51 -like 1 (S. cerevisiae), Aurora kinase B, and Phosphatase and tensin homolog (mutated in multiple advanced cancers 1); in cells of the individual suffering from CML; b) comparing the determined expression level for each gene respectively to a predetermined reference expression level; c) deducing therefrom if the individual suffering from CML is at risk of developing resistance to treatment by a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein or if the individual is likely to respond to treatment by a tyrosine kinase inhibitor targeting the BCR-ABL fusion protein.
PCT/EP2009/066973 2008-12-11 2009-12-11 Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients Ceased WO2010066891A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12168008P 2008-12-11 2008-12-11
US61/121,680 2008-12-11

Publications (2)

Publication Number Publication Date
WO2010066891A2 WO2010066891A2 (en) 2010-06-17
WO2010066891A3 true WO2010066891A3 (en) 2010-08-26

Family

ID=41650378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/066973 Ceased WO2010066891A2 (en) 2008-12-11 2009-12-11 Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients

Country Status (1)

Country Link
WO (1) WO2010066891A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164480A1 (en) * 2013-03-12 2014-10-09 Cepheid Methods of detecting cancer
WO2015049371A1 (en) * 2013-10-03 2015-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with chronic myeloid leukemia (cml) to a treatment with a tyrosine kinase inhibitor (tki)
RU2548766C1 (en) * 2013-12-19 2015-04-20 Государственное бюджетное учреждение здравоохранения Московской области " Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Method for determining clinical effectiveness in b-cell chronic lymphocytic leukaemia
CN106987599B (en) * 2017-03-28 2021-06-11 重庆医科大学 Zinc finger nuclease for inhibiting expression of human bcr-abl fusion gene or causing loss of function of human bcr-abl gene and application thereof
CN110129449A (en) * 2019-06-10 2019-08-16 北京大学人民医院(北京大学第二临床医学院) A kind of kit for detecting DDX11 gene mutation and its dedicated capture probe group

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
EP1533373A1 (en) * 2002-05-22 2005-05-25 Japan Represented by President of the University of Tokyo Method of judging sensibility to imatinib
WO2007120726A2 (en) * 2006-04-11 2007-10-25 The Regents Of The University Of California Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
EP1533373A1 (en) * 2002-05-22 2005-05-25 Japan Represented by President of the University of Tokyo Method of judging sensibility to imatinib
WO2007120726A2 (en) * 2006-04-11 2007-10-25 The Regents Of The University Of California Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CROSSMAN LUCY C ET AL: "In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.", HAEMATOLOGICA APR 2005, vol. 90, no. 4, April 2005 (2005-04-01), pages 459 - 464, XP002569600, ISSN: 1592-8721 *
FRANK O ET AL: "Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients", LEUKEMIA (BASINGSTOKE), vol. 20, no. 8, August 2006 (2006-08-01), pages 1400 - 1407, XP002568839, ISSN: 0887-6924 *
HANTSCHEL O ET AL: "The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia", MOLECULAR ONCOLOGY,, vol. 2, no. 3, 1 October 2008 (2008-10-01), pages 272 - 281, XP025475234, ISSN: 1574-7891, [retrieved on 20080723] *
VILLUENDAS R ET AL: "Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 20, no. 6, 1 June 2006 (2006-06-01), pages 1047 - 1054, XP008096484, ISSN: 0887-6924, [retrieved on 20060406] *
ZHOU LONGEN ET AL: "Small molecules targeting Rad51 recombinase synergize with imatinib and overcorne imatinib-resistance in CML", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 110, no. 11,Part 1, 1 November 2007 (2007-11-01), pages 143A - 144A, XP009129509, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2010066891A2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
Yuwen et al. Prognostic role of circulating exosomal miR-425-3p for the response of NSCLC to platinum-based chemotherapy
Reclusa et al. Exosomes as diagnostic and predictive biomarkers in lung cancer
Nishikawa et al. Tumor‐suppressive micro RNA‐218 inhibits cancer cell migration and invasion via targeting of LASP 1 in prostate cancer
WO2002061128A3 (en) Method of determining a chemotherapeutic regimen based on ercc1 expression
NZ593229A (en) Gene expression markers (gadd45b) for colorectal cancer prognosis
JP2015513529A5 (en)
CN110090226A (en) For the treating cancer in cancer patient and the method for predicting medicine response
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
MX2010002113A (en) Methods for detecting oligonucleotides.
WO2011109584A3 (en) Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2010066891A3 (en) Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients
WO2009103790A3 (en) Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
WO2008048986A3 (en) Gene array technique for predicting response in inflammatory bowel diseases
RU2015106714A (en) FORECASTING RESPONSE TO TREATMENT WITH JAK / STAT INHIBITOR
WO2012032519A3 (en) Methods of diagnosing parkinson's disease
Puente et al. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
WO2008036792A3 (en) Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
JP2016528914A5 (en)
WO2006012468A3 (en) Detection of oligonuleotides by dual hybridization
WO2007112350A3 (en) Method of assessing the metastatic status of a primary tumor
WO2010115997A3 (en) Method for determining survival prognosis of patients suffering from non-small cell lung cancer (nsclc)
WO2007128984A3 (en) Breast cancer makers
CA2517384A1 (en) Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus
EP2966448B1 (en) Method for the prediction or prognosis of the response of a human subject suffering from cancer to treatment with an antagonist of the nk1 receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09768078

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09768078

Country of ref document: EP

Kind code of ref document: A2